UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

AVROBIO, INC.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title of Class of Securities)

05455M100

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

⊠ Rule 13d-1(c)

o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 05455M100	SCHEDULE 13G/A	Page 2 of 9 Pages
---------------------	----------------	-------------------

	NAME OF BERG	DEING D	EDGOVG	
1	NAME OF REPORTING PERSONS			
	Deep Track Capital, LP			
_		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		
2	(a) o (b) x			
	SEC USE ONLY			
3	SEC USE OIVET			
4	CITIZENSHIP O	R PLACE	OF ORGANIZATION	
	Delaware			
		_	SOLE VOTING POWER	
		5	0	
	NUMBER OF SHARES		SHARED VOTING POWER	
BEN	EFICIALLY	6	4 070 400	
	OWNED BY EACH REPORTING		1,050,132	
RE			SOLE DISPOSITIVE POWER	
	PERSON WITH	7	0	
	***************************************	8	SHARED DISPOSITIVE POWER	
			1,050,132	
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSO		BENEFICIALLY OWNED BY EACH REPORTING PERSON		
9	1,050,132			
	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o			
10	CHECK II THE REGRESSILE THROUGH IN NOW (3) EXCEDDES CERTAIN SIERCES			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	2.41%			
10	TYPE OF REPORTING PERSON			
12	IA, OO			

CUSIP No. 05455M100	SCHEDULE 13G/A	Page 3 of 9 Pages
---------------------	----------------	-------------------

	NAME OF REPORTING PERSONS			
1	Deep Track Biotechnology Master Fund, Ltd.			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) 0 (b) x			
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
4	Cayman Islands			
	NUMBER OF SHARES BENEFICIALLY OWNED BY		SOLE VOTING POWER 0	
S BEN			SHARED VOTING POWER 1,050,132	
EACH REPORTING PERSON WITH		7	SOLE DISPOSITIVE POWER 0	
		8	SHARED DISPOSITIVE POWER 1,050,132	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
9	1,050,132			
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.41%			
12	TYPE OF REPORTING PERSON CO			

CUSIP No. 05455M100	SCHEDULE 13G/A	Page 4 of 9 Pages
---------------------	----------------	-------------------

1	NAME OF REPORTING PERSONS			
1	David Kroin			
	CHECK THE AP	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		
2	(a) 0			
	(b) x			
	SEC USE ONLY			
3				
	CITIZENSHIP OR PLACE OF ORGANIZATION			
4				
	United States	1	COLE VOTING POWER	
		5	SOLE VOTING POWER	
NIL	MADED OF		0	
	NUMBER OF SHARES BENEFICIALLY		SHARED VOTING POWER	
			1,050,132	
	VNED BY EACH		SOLE DISPOSITIVE POWER	
RE	PORTING	7	SOLE DISTOSITIVE TOWER	
F	PERSON WITH	N	0	
	***************************************	8	SHARED DISPOSITIVE POWER	
			1,050,132	
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		BENEFICIALLY OWNED BY EACH REPORTING PERSON		
9	1.050.122			
	1,050,132			
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
11	2.41%			
	TYPE OF REPORTING PERSON			
12				
	IN, HC			

CUSII	P No. 05455M100	SCHEDULE 13G/A	Page 5 of 9 Pages		
Item 1.	(a) Name of Issuer				
	AVROBIO, INC.				
Item 1.	(b) Address of Issuer's Principal Ex	ecutive Offices			
	One Kendall Square				
	Building 300, Suite 201				
	Cambridge, MA 02139				
Item 2.	(a) Names of Persons Filing:				
	(i) Deep Track Capital, LP (ii) Deep Track Biotechnology Mas (iii) David Kroin	ster Fund, Ltd.			
Item 2.	(b) Address of Principal Business O	office:			
		Greenwich, CT 06830 190 Elgin Ave, George Town, KY1-9001, Cayman Islands 0 Greenwich Ave, 3rd Floor, Greenwich, CT 06830			
Item 2.	(c) Citizenship:				
	(i) Delaware (ii) Cayman Islands (iii) United States				
Item 2.	(d) Title of Class of Securities				
	Common Stock, \$0.0001 par value	per share (the "Common Stock")			
Item 2.	(e) CUSIP No.:				
10011 20	05455M100				
CUSI	P No. 05455M100	SCHEDULE 13G/A	Page 6 of 9 Pages		
<u> </u>		ı			
Item 3.	If this statement is filed pursuant to	§§240.13d-1(b) or 240.13d-2(b) or (c), check whether the p	erson filing is a:		
		(4)	8		
(a)	☐ Broker or dealer registered under	section 15 of the Act (15 U.S.C. 780);			
(b)	\square Bank as defined in section 3(a)(6)	of the Act (15 U.S.C. 78c);			
(c)	☐ Insurance company as defined in	section 3(a)(19) of the Act (15 U.S.C. 78c);			
(d)	☐ Investment company registered un	nder section 8 of the Investment Company Act of 1940 (15 U.S	s.C. 80a-8);		
(e)	o An investment adviser in accordan	nce with §240.13d-1(b)(1)(ii)(E);			
(f)	☐ An employee benefit plan or endo	wment fund in accordance with §240.13d-1(b)(1)(ii)(F);			
(g)	\square A parent holding company or con	trol person in accordance with §240.13d-1(b)(1)(ii)(G);			
(h)	☐ A savings associations as defined	in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C	C. 1813);		
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);				
(j)	☐ A non-U.S. institution in accordan	nce with §240.13d-1(b)(1)(ii)(J);			
(k)	☐ A group, in accordance with §240 specify the type of institution:	.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accord	ance with §240.13d-1(b)(1)(ii)(J), please		
		1			
CUSI	P No. 05455M100	SCHEDULE 13G/A	Page 7 of 9 Pages		

Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2021, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

The amount beneficially owned by each Reporting Person is determined based on 43,652,470 shares of Common Stock outstanding.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not Applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.

Item 8. Identification and Classification of Members of the Group

Not Applicable.

Item 9. Notice of Dissolution of Group

Not Applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2022

Deep Track Capital, LP

By: /s/ David Kroin

David Kroin, Managing Member of the General Partner of the

Investment Adviser

Deep Track Biotechnology Master Fund, Ltd.

By: /s/ David Kroin

David Kroin, Director

David Kroin

By: /s/ David Kroin

David Kroin

Exhibit I

JOINT FILING STATEMENT

PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated: February 14, 2022

Deep Track Capital, LP

By: /s/ David Kroin

David Kroin, Managing Member of the General Partner of the

Investment Adviser

Deep Track Biotechnology Master Fund, Ltd.

By: /s/ David Kroin

David Kroin, Director

David Kroin

By: /s/ David Kroin

David Kroin